BioMarin Pharmaceutical Inc.

BIT:1BMRN Stock Report

Market Cap: €12.8b

BioMarin Pharmaceutical Valuation

Is 1BMRN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 1BMRN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
€214.41
Fair Value
69.1% undervalued intrinsic discount
28
Number of Analysts

Below Fair Value: 1BMRN (€66.34) is trading below our estimate of fair value (€214.41)

Significantly Below Fair Value: 1BMRN is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1BMRN?

Key metric: As 1BMRN is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 1BMRN. This is calculated by dividing 1BMRN's market cap by their current earnings.
What is 1BMRN's PE Ratio?
PE Ratio31.9x
EarningsUS$426.86m
Market CapUS$13.89b

Price to Earnings Ratio vs Peers

How does 1BMRN's PE Ratio compare to its peers?

The above table shows the PE ratio for 1BMRN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average20.8x
REC Recordati Industria Chimica e Farmaceutica
26.1x11.0%€10.9b
UTHR United Therapeutics
11.5x8.0%US$13.8b
EXEL Exelixis
19.7x22.3%US$10.3b
SOBI Swedish Orphan Biovitrum
25.8x17.2%SEK 100.2b
1BMRN BioMarin Pharmaceutical
31.9x20.2%€13.9b

Price-To-Earnings vs Peers: 1BMRN is expensive based on its Price-To-Earnings Ratio (31.9x) compared to the peer average (20.8x).

Price to Earnings Ratio vs Industry

How does 1BMRN's PE Ratio compare vs other companies in the European Biotechs Industry?

5 CompaniesPrice / EarningsEstimated GrowthMarket Cap
1BMRN 31.9xIndustry Avg. 17.7xNo. of Companies5PE01632486480+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 1BMRN is expensive based on its Price-To-Earnings Ratio (31.9x) compared to the European Biotechs industry average (17.7x).

Price to Earnings Ratio vs Fair Ratio

What is 1BMRN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1BMRN PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio31.9x
Fair PE Ratio37.5x

Price-To-Earnings vs Fair Ratio: 1BMRN is good value based on its Price-To-Earnings Ratio (31.9x) compared to the estimated Fair Price-To-Earnings Ratio (37.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 1BMRN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€66.34
€89.58
+35.0%
15.4%€116.70€60.20n/a28
Mar ’26€66.96
€92.45
+38.1%
15.4%€120.39€62.11n/a28
Feb ’26€61.64
€94.15
+52.7%
16.1%€123.96€63.45n/a27
Jan ’26€63.38
€93.89
+48.1%
16.5%€122.54€62.72n/a26
Dec ’25€62.30
€92.71
+48.8%
16.7%€121.01€61.93n/a28
Nov ’25€61.04
€89.54
+46.7%
16.8%€116.94€59.85n/a27
Oct ’25€63.32
€94.23
+48.8%
16.4%€125.06€64.78n/a25
Sep ’25€81.50
€99.39
+21.9%
14.2%€125.83€64.71n/a25
Aug ’25€79.04
€100.94
+27.7%
15.2%€129.15€66.42n/a25
Jul ’25€77.24
€101.18
+31.0%
15.9%€130.82€67.28n/a26
Jun ’25€68.54
€101.03
+47.4%
14.3%€129.37€73.93n/a26
May ’25€75.78
€102.79
+35.6%
14.3%€130.87€74.78n/a28
Apr ’25€81.70
€101.35
+24.1%
14.2%€129.19€73.82n/a28
Mar ’25€80.04
€101.50
+26.8%
14.2%€129.02€73.73€66.9628
Feb ’25€81.04
€102.37
+26.3%
15.7%€138.35€71.94€61.6428
Jan ’25€87.80
€101.21
+15.3%
18.0%€154.87€71.06€63.3828
Dec ’24€84.04
€100.67
+19.8%
18.5%€154.75€71.00€62.3027
Nov ’24€79.10
€108.37
+37.0%
19.4%€175.07€73.81€61.0425
Oct ’24€84.12
€108.56
+29.1%
19.5%€173.14€73.00€63.3224
Sep ’24€86.50
€106.64
+23.3%
20.0%€170.51€65.44€81.5024
Aug ’24€78.66
€105.31
+33.9%
20.1%€168.44€63.74€79.0424
Jul ’24€80.50
€108.33
+34.6%
21.6%€183.28€66.90€77.2423
Jun ’24€82.16
€107.76
+31.2%
20.7%€181.50€62.62€68.5424
May ’24€84.86
€107.76
+27.0%
20.7%€181.50€62.62€75.7824
Apr ’24€88.90
€110.94
+24.8%
20.9%€185.68€68.70€81.7024
Mar ’24€95.33
€114.87
+20.5%
19.6%€187.58€69.40€80.0423
Analyst Price Target
Consensus Narrative from 28 Analysts
€89.82
Fair Value
26.1% undervalued intrinsic discount
28
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/28 03:46
End of Day Share Price 2025/03/28 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BioMarin Pharmaceutical Inc. is covered by 55 analysts. 28 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Ishan MajumdarBaptista Research
Ying HuangBarclays